NCT03741673

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

Recruiting now Phase 3 Last updated 5 September 2025

What this trial tests

Phase 3 trial testing Quality-of-Life Assessment in Malignant Neoplasm in 180 participants. Currently enrolling.

Timeline

8 November 2018

Primary endpoint
31 January 2027

31 January 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	8 November 2018
Primary completion	31 January 2027
Estimated completion	31 January 2027
Sites	1 location across United States

Drugs / interventions tested

• Quality-of-Life Assessment
• Questionnaire Administration
• Stereotactic Radiosurgery

Conditions studied

• Malignant Neoplasm — all drugs for Malignant Neoplasm →
• Metastatic Malignant Neoplasm in the Brain — all drugs for Metastatic Malignant Neoplasm in the Brain →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Malignant Neoplasm or Metastatic Malignant Neoplasm in the Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of focused, high-dose radiation given in a single session to the tumors, with a minimal dose given to uninvolved areas of the brain.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Treatment strategies for breast cancer brain metastases.
   Bailleux C, Eberst L, Bachelot T. · · 2021 · cited 170× · PMID 33250512 · DOI 10.1038/s41416-020-01175-y
2. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
   Aizer AA, Lamba N, Ahluwalia MS, Aldape K, et al · · 2022 · cited 116× · PMID 35762249 · DOI 10.1093/neuonc/noac118
3. Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives.
   Watase C, Shiino S, Shimoi T, Noguchi E, et al · · 2021 · cited 68× · PMID 33802424 · DOI 10.3390/cancers13051078
4. Current status and recent advances in resection cavity irradiation of brain metastases.
   Minniti G, Niyazi M, Andratschke N, Guckenberger M, et al · · 2021 · cited 52× · PMID 33858474 · DOI 10.1186/s13014-021-01802-9
5. Brain metastases: An update on the multi-disciplinary approach of clinical management.
   Mitchell DK, Kwon HJ, Kubica PA, Huff WX, et al · · 2022 · cited 39× · PMID 33864773 · DOI 10.1016/j.neuchi.2021.04.001
6. Update on the Management of Brain Metastasis.
   Singh K, Saxena S, Khosla AA, McDermott MW, et al · · 2022 · cited 38× · PMID 36422836 · DOI 10.1007/s13311-022-01312-w
7. Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions.
   Mantovani C, Gastino A, Cerrato M, Badellino S, et al · · 2021 · cited 37× · PMID 34796118 · DOI 10.3389/fonc.2021.772789
8. Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.
   Nguyen TK, Sahgal A, Detsky J, Atenafu EG, et al · · 2020 · cited 37× · PMID 31412120 · DOI 10.1093/neuonc/noz144